CL2020000676A1 - Composiciones y métodos para modular el crecimiento del cabello. - Google Patents

Composiciones y métodos para modular el crecimiento del cabello.

Info

Publication number
CL2020000676A1
CL2020000676A1 CL2020000676A CL2020000676A CL2020000676A1 CL 2020000676 A1 CL2020000676 A1 CL 2020000676A1 CL 2020000676 A CL2020000676 A CL 2020000676A CL 2020000676 A CL2020000676 A CL 2020000676A CL 2020000676 A1 CL2020000676 A1 CL 2020000676A1
Authority
CL
Chile
Prior art keywords
hair growth
methods
compositions
modulate hair
growth
Prior art date
Application number
CL2020000676A
Other languages
English (en)
Inventor
William E Lowry
Heather R Christofk
Aimee Flores
Matilde Miranda
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CL2020000676A1 publication Critical patent/CL2020000676A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN INHIBIDORES DE LA CADENA DE TRANSPORTE DE ELECTRONES (ETC), QUE SON CAPACES DE PROMOVER EL CRECIMIENTO DEL CABELLO. LA DESCRIPCIÓN HACE REFERENCIA TAMBIÉN A MÉTODOS PARA PROMOVER EL CRECIMIENTO DEL CABELLO O TRATAR AFECCIONES O TRASTORNOS QUE AFECTAN EL CRECIMIENTO DEL CABELLO, TAL COMO LA CALVICIE O ALOPECIA.
CL2020000676A 2017-09-29 2020-03-16 Composiciones y métodos para modular el crecimiento del cabello. CL2020000676A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762566031P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
CL2020000676A1 true CL2020000676A1 (es) 2020-09-25

Family

ID=65903207

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000676A CL2020000676A1 (es) 2017-09-29 2020-03-16 Composiciones y métodos para modular el crecimiento del cabello.

Country Status (16)

Country Link
US (1) US20200253917A1 (es)
EP (1) EP3687528A4 (es)
JP (1) JP2020536048A (es)
KR (1) KR20200062242A (es)
CN (1) CN111295188A (es)
AU (1) AU2018339064A1 (es)
BR (1) BR112020003349A2 (es)
CA (1) CA3077359A1 (es)
CL (1) CL2020000676A1 (es)
EA (1) EA202090855A1 (es)
IL (1) IL272827A (es)
MX (1) MX2020002389A (es)
PE (1) PE20210464A1 (es)
PH (1) PH12020500300A1 (es)
SG (2) SG11202001516QA (es)
WO (1) WO2019067860A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010101A (es) 2017-02-24 2019-10-15 Univ California Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
AU2018294351B2 (en) 2017-06-30 2022-12-22 The Regents Of The University Of California Compositions and methods for modulating hair growth
KR102561912B1 (ko) * 2021-04-09 2023-07-31 차의과학대학교 산학협력단 세팔로틴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 탈모방지 또는 발모촉진용 조성물
CN113694063A (zh) * 2021-08-31 2021-11-26 佛山市第一人民医院（中山大学附属佛山医院） 一种组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
DE60127827T2 (de) * 2000-02-23 2007-12-27 Orentreich Foundation For The Advancement Of Science, Inc. Verwendung von einem insulin-sensibilisator in der behandlung von alopecia
WO2006030439A2 (en) * 2004-09-17 2006-03-23 Biomas Ltd. Compositions and methods for inducing hair growth
EP1919449A2 (en) * 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8343962B2 (en) * 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8563500B2 (en) * 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
BR112013014021A8 (pt) * 2010-12-06 2017-10-03 Follica Inc Métodos para tratamento de calvície e promoção de crescimento de cabelos
CN106880693A (zh) * 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法

Also Published As

Publication number Publication date
SG11202001516QA (en) 2020-03-30
EP3687528A4 (en) 2021-07-21
EA202090855A1 (ru) 2020-06-26
BR112020003349A2 (pt) 2020-08-18
EP3687528A1 (en) 2020-08-05
SG10202109849SA (en) 2021-10-28
PH12020500300A1 (en) 2020-11-09
MX2020002389A (es) 2020-10-01
PE20210464A1 (es) 2021-03-08
CN111295188A (zh) 2020-06-16
KR20200062242A (ko) 2020-06-03
IL272827A (en) 2020-04-30
JP2020536048A (ja) 2020-12-10
US20200253917A1 (en) 2020-08-13
AU2018339064A1 (en) 2020-02-27
CA3077359A1 (en) 2019-04-04
WO2019067860A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
CL2020000676A1 (es) Composiciones y métodos para modular el crecimiento del cabello.
CL2019003886A1 (es) Composiciones y métodos para modular el crecimiento del cabello.
CO2017013234A2 (es) Mezcla para tratar fertilizantes que contienen urea
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2022010241A2 (es) Inhibidores de sos1
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CL2020001453A1 (es) Compuestos y métodos para modular la expresión de angiotensinógeno. (divisional solicitud 201800899)
CL2020002821A1 (es) Piridazinonas como inhibidoras de parp7.
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2018003213A1 (es) Inhibidores enzimáticos.
CL2018000429A1 (es) Moduladores de la expresión de kras
UY37143A (es) Compuestos macrocíclicos útiles como inmunomoduladores de las interacciones proteína/proteína pd-1/pd-l1 y cd80/pd-l1
UY36076A (es) Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
ECSP19083923A (es) Inhibidores pirazólicos de magl
BR112017027147A2 (pt) agente estimulante de restauração/crescimento de cabelo
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
AR093310A1 (es) Composiciones y metodos para mejorar el crecimiento de las plantas
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
CL2019003397A1 (es) Inhibidores pirazólicos de magl.